What it is
Sermorelin is a man-made copy of growth hormone-releasing hormone, the signal your own hypothalamus — a control centre deep in the brain — sends to the pituitary gland. It uses the first 29 of the 44 building blocks of the natural hormone, and that shortened version works just as well at triggering growth hormone release.
It is also called GHRH (1-29) or GRF (1-29). It was approved by the FDA in 1997 for children with growth hormone deficiency under the brand name Geref. The maker stopped production in 2008 for business reasons, not safety reasons, and it is still made by compounding pharmacies for off-label use.
Sermorelin was the first of its kind, before CJC-1295 and tesamorelin. That makes it the closest match to the signal the body already makes, but also the easiest to break down. An enzyme called DPP-4 cuts it apart quickly, so it only lasts about 10 to 20 minutes in the blood.
That short life is a feature as much as a limit. Because it clears fast, the growth hormone comes out in sharp bursts that look like the body's own, and the body's natural brake still applies.
It arrives as a dry powder in a sealed glass vial. You add bacteriostatic water — sterile water with a preservative so it keeps for weeks — then inject it just under the skin.
Sermorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), consisting of the first 29 amino acids of the endogenous 44-amino-acid hypothalamic peptide. The truncated sequence retains full biological activity at the GHRH receptor on anterior pituitary somatotrophs. It is also designated GHRH (1-29) or GRF (1-29).
FDA-approved in 1997 as Geref for paediatric growth hormone deficiency, it was withdrawn commercially in 2008 for market rather than safety reasons and remains available through compounding pharmacies off-label.
Sermorelin is the original GHRH analogue, predating CJC-1295 and tesamorelin and carrying no stabilising modifications. Dipeptidyl aminopeptidase 4 (DPP-4) recognises the Tyr-Ala sequence at the N-terminus and cleaves it, giving a half-life of roughly 10 to 20 minutes — substantially shorter than the engineered analogues.
What that preserves is pulsatility. Rapid clearance produces a GH response resembling native secretory bursts, and those bursts remain subject to somatostatin, the endogenous inhibitory arm. That feedback makes supraphysiological GH levels of the kind associated with exogenous somatropin very difficult to reach.
Sermorelin plus a GHRP remains the standard two-arm approach to the axis, with ipamorelin the usual partner.
How it works
The hypothalamus sends out growth hormone-releasing hormone in pulses through the day, with the largest pulses during deep sleep. When that signal reaches the pituitary gland, the gland makes and releases growth hormone.
Sermorelin copies that exact step. Injected under the skin, it reaches the pituitary, docks onto the same targets, and triggers a burst of growth hormone. That growth hormone travels to the liver, which converts it into IGF-1 — the messenger that does most of the real work: releasing stored fat, building muscle protein, repairing tissue, and making collagen.
The body keeps control. A hormone called somatostatin acts as a brake and slows things down when growth hormone rises. That makes Sermorelin self-limiting. Injecting growth hormone itself skips this system entirely, and over time the body cuts back its own production to compensate. Sermorelin avoids that because it sends a signal rather than the finished product.
Research also suggests Sermorelin nudges the pituitary to make more growth hormone, not just release what is stored, which may help keep the gland working as you age. This idea comes from the Walker 2006 editorial in Clinical Interventions in Aging and is a theory backed by mechanism rather than large trials.
Sermorelin peaks in the blood 5 to 20 minutes after injection and clears in about 10 to 20 minutes. The knock-on effects inside the pituitary carry on for hours, which is why once a day is enough.
GHRH is secreted by the hypothalamus in pulses, the largest coinciding with slow-wave sleep. Sermorelin reproduces that signal: subcutaneous administration delivers peptide to the anterior pituitary, where it binds GHRH receptors on somatotrophs and triggers GH synthesis and pulsatile release. Hepatic conversion yields IGF-1, the effector for lipolysis, muscle protein synthesis, tissue repair and collagen production.
The response is fully regulated by somatostatin. Rising GH recruits the inhibitory arm, capping the ceiling of the response and making the stimulus self-limiting. Exogenous somatropin bypasses this loop and suppresses endogenous output; upstream stimulation does not, because the pituitary retains control over how much it releases.
Sermorelin also stimulates hGH gene transcription, implying an increase in secretory capacity rather than simple release of stored hormone. The concept of pituitary recrudescence — regular GHRH stimulation preserving glandular function against age-related decline of the GH neuroendocrine axis — derives from the Walker 2006 editorial in Clinical Interventions in Aging, a theoretical framework rather than a controlled trial.
Pharmacokinetics: half-life approximately 10 to 20 minutes, adult clearance 2.4 to 2.8 litres per minute, peak plasma concentration within 5 to 20 minutes of subcutaneous dosing. Downstream signalling persists for hours after the peptide has cleared, supporting once-daily administration.
Positioning among GHRH analogues: Sermorelin is unmodified 1-29 and the most DPP-4-vulnerable. CJC-1295 (no DAC) substitutes four residues for enzymatic resistance, giving greater stability and a cleaner side effect profile while still clearing fast enough to preserve pulsatility. Tesamorelin uses the full 44-amino-acid sequence with an N-terminal chemical cap blocking DPP-4, with the most extensive clinical data and the highest cost. All three converge on the same receptor; selection turns on stability, side effect profile, cost and individual response.
What it does
Sleep: this is usually the first thing to shift. Dosing before bed adds to the growth hormone surge that already happens in deep sleep, and users report deeper, more restorative nights.
Recovery: growth hormone speeds tissue repair. Active people report faster recovery between sessions and better healing of minor injuries, driven by IGF-1's effect on collagen, protein building and cell repair.
Body composition: higher growth hormone and IGF-1 support muscle growth and fat burning. In older adults, sustained GHRH treatment increased lean muscle and reduced body fat. Fat loss tends to favour the abdomen.
Energy and metabolism: more energy, less lethargy and fatigue, a higher metabolic rate, and support for the way cells make ATP, the fuel molecule.
Heart, skin and bone: better cardiovascular endurance and oxygen uptake by cells, more collagen for skin quality, faster cell renewal, and greater bone density.
Brain: healthy growth hormone levels support thinking and mental clarity.
The pituitary: unlike injected growth hormone, which can dial down the gland over time, Sermorelin stimulates it.
Sleep: bedtime dosing superimposes the exogenous GHRH signal on the slow-wave-sleep pulse; improved sleep quality is the most consistently reported early effect, though Merriam et al. (2003) noted no sleep improvement with short-acting GHRH in that review.
Regenerative: accelerated tissue repair via IGF-1-mediated collagen synthesis, protein synthesis and cellular regeneration; faster post-exercise recovery and improved healing of minor injuries.
Body composition: sustained GHRH treatment in ageing adults increased lean mass and reduced adipose tissue, with a preference for the abdominal depot consistent with GH's known effect on visceral fat. Changes are gradual, becoming apparent over 3 to 6 months.
Metabolic and bioenergetic: increased metabolic rate, increased energy with reduced lethargy and fatigue, support for cellular ATP generation.
Cardiovascular and skeletal: enhanced cardiovascular endurance and cellular oxygen uptake; increased bone density.
CNS: cognitive support mediated by restored GH and IGF-1 rather than direct central action; six months of sermorelin acetate improved fluid intelligence measures including working memory, planning and organisation, selective attention and processing speed in healthy older adults.
Axis integrity: stimulation rather than suppression of the somatotroph population, with pulsatility and somatostatin feedback intact — the basis of the pituitary recrudescence argument for long-term use.
Benefits
Evidence grades: what the labels mean
- Human trials Supported by randomised or placebo-controlled human trials.
- Limited human data Some human evidence, such as pilot studies, case reports or observational data, but no controlled trials.
- Animal or lab only Shown in animal or cell studies only; not yet tested in people.
- Anecdotal No published studies; based on user reports or theory.
Each grade reflects the strongest published support for that specific claim, not for the compound as a whole.
- Growth hormone is released in natural bursts, the way the body does it, rather than as a constant elevated level.Limited human data
- The body's own brake still works, so it is very hard to overshoot.Limited human data
- Deeper, more restorative sleep — usually the first benefit noticed.Anecdotal
- Faster recovery between training sessions and better healing of minor injuries.Anecdotal
- More lean muscle, more strength and better muscle tone.Limited human data
- Less body fat, especially around the abdomen.Limited human data
- More energy, less lethargy and fatigue.Limited human data
- Helps cells generate ATP, the molecule cells run on.Anecdotal
- Increases metabolism.Anecdotal
- Better cardiovascular endurance and oxygen uptake by cells.Anecdotal
- More collagen, which improves skin quality and appearance.Limited human data
- Faster renewal of cells.Anecdotal
- Increases bone density.Anecdotal
- Supports thinking and mental clarity through healthy growth hormone levels.Human trials
- Stimulates the pituitary rather than shutting it down, which matters for long-term use.Anecdotal
- Much cheaper than tesamorelin for what is the same pathway.Anecdotal
- Physiological, pulsatile GH release with intact somatostatin feedback — preferable to the sustained elevation of exogenous somatropin or long-acting analogues.Limited human data
- Self-limiting response; supraphysiological GH levels and the associated acromegalic features are very difficult to reach.Limited human data
- Improved sleep quality, the earliest and most consistently reported effect.Anecdotal
- Accelerated post-exercise recovery and soft-tissue repair via IGF-1.Anecdotal
- Lean mass accrual, increased strength and muscle tone.Limited human data
- Reduced adipose tissue, with a preference for the abdominal depot.Limited human data
- Increased energy; reduced lethargy and fatigue.Limited human data
- Supports cellular ATP generation.Anecdotal
- Increased metabolic rate.Anecdotal
- Enhanced cardiovascular endurance and cellular oxygen uptake.Anecdotal
- Increased collagen synthesis, improving skin quality and appearance.Limited human data
- Accelerated cellular regeneration.Anecdotal
- Increased bone density.Anecdotal
- Cognitive support via restored GH and IGF-1; improved fluid intelligence measures after six months in healthy older adults.Human trials
- Pituitary preservation — hGH gene transcription and the pituitary recrudescence hypothesis (Walker, 2006), a theoretical advantage for long-term use.Anecdotal
- Favourable safety profile relative to synthetic HGH and older, less selective GHRPs.Limited human data
- Substantially lower cost than tesamorelin for the same receptor pathway.Anecdotal
What to expect
Weeks 1 to 4: sleep improves first. Many people report deeper, more restorative sleep within the first 2 weeks. This is the most consistently reported early effect.
Weeks 3 to 6: recovery from training starts to improve and muscles feel less sore between sessions. Some people notice better mood and mental clarity in this window as IGF-1 levels settle.
Weeks 6 to 12: body composition changes start to show if diet and training are in place — more muscle tone, a gradual drop in body fat. Subtle at first.
Months 3 to 6: the biggest body composition changes happen here. Lean mass up, body fat down, and the benefits of better sleep and recovery add up into visible results.
This is a slow-building tool, not a quick fix. It is gradually shifting growth hormone and IGF-1 towards a more youthful profile, and that takes months.
Some things blunt the response. An untreated underactive thyroid can significantly reduce how well Sermorelin works — fix that first. Obesity, high blood sugar and raised free fatty acids also dull the pituitary's response. Sort out diet, training and general metabolic health before adding peptides.
Users also report that effects can feel more subtle than with CJC-1295 or tesamorelin, which fits with Sermorelin's faster breakdown. A few report that it seems to work less well after several months, with IGF-1 levels flattening or falling.
Weeks 1 to 4: sleep quality improves first, frequently within the first 2 weeks, and is the most consistently reported early effect.
Weeks 3 to 6: recovery improves, with reduced inter-session soreness. Mood and mental clarity gains are reported in this window as IGF-1 stabilises.
Weeks 6 to 12: visible body composition change begins where diet and training are already in place — increased muscle tone, gradual fat reduction.
Months 3 to 6: the largest body composition shifts occur, with lean mass accrual, fat reduction and the compounding effect of improved sleep and recovery.
Sermorelin is a slow-building intervention. It shifts the GH/IGF-1 axis towards a more youthful profile over months rather than producing acute change.
Blunting factors are mechanistically specific. Untreated hypothyroidism markedly reduces effectiveness and should be corrected before starting. Obesity, hyperglycaemia and elevated free fatty acids all attenuate the somatotroph response to GHRH stimulation. Veldhuis et al. (1991) documented dual defects in pulsatile GH secretion and clearance underlying the hyposomatotropism of obesity.
In practice, some users find the response more subtle than with CJC-1295 or tesamorelin, consistent with the shorter half-life and faster DPP-4 degradation. Reports of IGF-1 plateauing or declining after several months raise the question of receptor downregulation; the usual responses are adding ipamorelin at a different time of day to recruit the ghrelin pathway, or rotating to CJC-1295 for a period. Monitoring IGF-1 over 6 to 8 weeks is the practical way to judge individual response.
Reconstitution and dosing
The standard dose is 200 to 500 mcg once a day, injected under the skin about 30 minutes before bed, on an empty stomach. Leave at least 2 hours after eating. Food, especially carbohydrate, raises insulin, and insulin blunts the growth hormone response. Bedtime also lines the dose up with the body's largest natural growth hormone pulse in early deep sleep. A cycle runs 3 to 6 months.
Dosing by goal: general wellness and anti-ageing, 200 to 300 mcg before bed. Performance and recovery, 300 to 500 mcg before bed. For maximum effect, some split it twice daily: 300 mcg in the morning fasted plus 300 mcg before bed. Morning-only dosing is fine too if bedtime dosing disturbs sleep — inject fasted and wait at least 30 minutes, ideally 2 hours, before eating.
With ipamorelin: 200 to 300 mcg Sermorelin plus 100 to 200 mcg ipamorelin, pinned together before bed, fasted, daily, for 8 to 12 weeks.
Mixing: a 5 mg vial with 2 mL of bacteriostatic water gives 250 mcg per 10 units on an insulin syringe, so 300 mcg is 12 units. Add the water slowly down the inside wall of the vial and swirl gently — do not shake.
Where to inject: under the skin of the abdomen or thigh. Rotate sites so scar tissue does not build up.
Storage: keep the dry powder in the fridge at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius), or the freezer for longer storage, away from light. Once mixed, keep it in the fridge and use it within 28 days. Do not freeze it after mixing. Throw it away if it turns cloudy or discoloured.
A longer step-up plan also exists: 200 mcg for weeks 1-4, then 300, 400 and 500 mcg in four-week blocks, running 12 to 16 weeks with a 6 to 8 week break. A higher version starts at 300 mcg and finishes at 600 mcg.
Standard protocol: 200 to 500 mcg subcutaneously, once daily, 30 minutes before bed, fasted at least 2 hours post-prandial, cycled 3 to 6 months. Both timing constraints are mechanistic — postprandial insulin and elevated free fatty acids attenuate the somatotroph response, and bedtime administration superimposes the signal on the slow-wave-sleep pulse.
Per-goal tiers: general wellness and anti-ageing, 200 to 300 mcg before bed; performance and recovery, 300 to 500 mcg before bed; maximum effect as a twice-daily split, 300 mcg fasted in the morning plus 300 mcg before bed. Morning-only administration is acceptable where bedtime dosing disrupts sleep, injected fasted with at least 30 minutes, ideally 2 hours, before food.
With ipamorelin: Sermorelin 200 to 300 mcg plus ipamorelin 100 to 200 mcg, co-administered pre-sleep and fasted, daily, for 8 to 12 weeks. GHRH plus GHRP is synergistic, reported at 77 to 225 percent greater GH release than either compound alone: GHRH increases the number of somatotrophs secreting, while ghrelin receptor agonists increase output per cell and suppress somatostatin, removing the brake.
Reconstitution: 5 mg vial in 2 mL bacteriostatic water yields 250 mcg per 10 units on an insulin syringe; 300 mcg equals 12 units. Add diluent down the vial wall and swirl; do not shake. Subcutaneous injection into abdomen or thigh, rotating sites to avoid scar tissue.
Storage: lyophilised vials at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius), or frozen for longer periods, protected from light. Reconstituted solution refrigerated and used within 28 days; do not freeze. Unlike tesamorelin, Sermorelin has no temperature-dependent solubility issues causing cold gelling. Discard if cloudy or discoloured.
An alternative four-week titration ladder also appears in practice: 200, 300, 400 then 500 mcg once daily across weeks 1-4, 5-8, 9-12 and 13-16, cycled 12 to 16 weeks with a 6 to 8 week washout; the maximum variant shifts the ladder one step to 300, 400, 500 and 600 mcg.
Do not combine with exogenous growth hormone; negative feedback suppresses the pituitary response and defeats the purpose.
Standard (solo), 5 mg vial
Mix with 2 mL (200 units) of bacteriostatic water.
2.5 mg/mL · 25 mcg per unit
Cycle: 3 to 6 months · Frequency: 1×/day, 30 minutes before bed, fasted at least 2 hours after eating
| When | Dose | Draw | How often |
|---|---|---|---|
| Starting | 200 mcg | 8 units | 1×/day |
| Full | 500 mcg | 20 units | 1×/day |
Standard (with ipamorelin), 5 mg vial
Mix with 2 mL (200 units) of bacteriostatic water.
2.5 mg/mL · 25 mcg per unit
Cycle: 8 to 12 weeks · Frequency: 1×/day before bed, fasted, pinned together with ipamorelin 100 to 200 mcg
| When | Dose | Draw | How often |
|---|---|---|---|
| Starting | 200 mcg | 8 units | 1×/day |
| Full | 300 mcg | 12 units | 1×/day |
Alternative protocols
Alternative protocols reflect older community practice and are kept for reference.
Alternative, 5 mg vial — standard protocol
Mix with 2.5 mL (250 units) of bacteriostatic water.
2 mg/mL · 20 mcg per unit
Cycle: 12–16 weeks, then a 6–8 week washout · Frequency: 1×/day at bedtime, fasted at least 1.5 hours after the last meal
| When | Dose | Draw | How often |
|---|---|---|---|
| Weeks 1–4 | 200 mcg | 10 units | 1×/day |
| Weeks 5–8 | 300 mcg | 15 units | 1×/day |
| Weeks 9–12 | 400 mcg | 20 units | 1×/day |
| Weeks 13–16 | 500 mcg | 25 units | 1×/day |
Alternative, 5 mg vial — maximum protocol
Mix with 2.5 mL (250 units) of bacteriostatic water.
2 mg/mL · 20 mcg per unit
Cycle: 12–16 weeks, then a 6–8 week washout · Frequency: 1×/day at bedtime, fasted at least 1.5 hours after the last meal
| When | Dose | Draw | How often |
|---|---|---|---|
| Weeks 1–4 | 300 mcg | 15 units | 1×/day |
| Weeks 5–8 | 400 mcg | 20 units | 1×/day |
| Weeks 9–12 | 500 mcg | 25 units | 1×/day |
| Weeks 13–16 | 600 mcg | 30 units | 1×/day |
Alternative, 10 mg vial — standard protocol
Mix with 2.5 mL (250 units) of bacteriostatic water.
4 mg/mL · 40 mcg per unit
Cycle: 12–16 weeks, then a 6–8 week washout · Frequency: 1×/day at bedtime, fasted at least 1.5 hours after the last meal
| When | Dose | Draw | How often |
|---|---|---|---|
| Weeks 1–4 | 200 mcg | 5 units | 1×/day |
| Weeks 5–8 | 300 mcg | 7.5 units | 1×/day |
| Weeks 9–12 | 400 mcg | 10 units | 1×/day |
| Weeks 13–16 | 500 mcg | 12.5 units | 1×/day |
Alternative, 10 mg vial — maximum protocol
Mix with 2.5 mL (250 units) of bacteriostatic water.
4 mg/mL · 40 mcg per unit
Cycle: 12–16 weeks, then a 6–8 week washout · Frequency: 1×/day at bedtime, fasted at least 1.5 hours after the last meal
| When | Dose | Draw | How often |
|---|---|---|---|
| Weeks 1–4 | 300 mcg | 7.5 units | 1×/day |
| Weeks 5–8 | 400 mcg | 10 units | 1×/day |
| Weeks 9–12 | 500 mcg | 12.5 units | 1×/day |
| Weeks 13–16 | 600 mcg | 15 units | 1×/day |
5 mg in 2 mL is 2.5 mg/mL, or 25 mcg per unit. Draw 8 units (0.08 mL) for 200 mcg.
Who should avoid it
- Anyone with active cancer or a history of cancer — growth hormone and IGF-1 can speed up tumour growth.
- Anyone known to be allergic to Sermorelin or anything else in the vial.
- Anyone with lesions inside the skull — it has not been studied in these people.
- Anyone pregnant (Category C) or breastfeeding.
- Anyone with an untreated underactive thyroid — fix the thyroid first, because it can strongly reduce how well Sermorelin works.
- Anyone with epilepsy — use caution.
- Anyone with diabetes or high blood sugar — the response may be blunted, and take extra care if you have diabetic eye damage (diabetic retinopathy).
- Anyone who is obese — the pituitary response may be reduced.
- Anyone who is acutely, critically ill.
- Anyone with Prader-Willi syndrome, a genetic condition affecting appetite and growth — speak to a doctor first.
- Anyone taking steroid medicines (glucocorticoids such as prednisone) or thyroid medication — these can interfere, so talk to your doctor first.
- Do not use it alongside injected growth hormone. The extra hormone shuts down the signal Sermorelin is trying to send.
- Take extra care if you are prone to allergies.
- Active malignancy or history of malignancy — GH and IGF-1 may accelerate tumour growth.
- Known hypersensitivity to Sermorelin or its components.
- Intracranial lesions — not studied in this population.
- Pregnancy (Category C) and breastfeeding.
- Untreated hypothyroidism — significantly reduces efficacy; treat before starting, as thyroid status governs response and GH alters T4 to T3 conversion.
- Epilepsy — caution.
- Diabetes or significant hyperglycaemia — may blunt the somatotroph response; diabetic retinopathy is a contraindication.
- Obesity — reduced pituitary response to GHRH stimulation.
- Acute critical illness.
- Prader-Willi syndrome — physician consultation required.
- Concurrent glucocorticoids, which may interfere with Sermorelin's effects, and concurrent thyroid medication — physician consultation required.
- Exogenous growth hormone injections — negative feedback from exogenous GH suppresses the pituitary response to Sermorelin, defeating the purpose.
- Caution in atopic individuals.
- Untreated hypothyroidism, uncontrolled glycaemia, elevated free fatty acids and obesity should be corrected first; all blunt GHRH-stimulated GH release.
Side effects
- Reaction where you inject — pain, redness, swelling or itching. This is the most common one, seen in roughly 1 in 6 patients in clinical studies.
- Facial flushing, usually brief, sometimes lasting a few minutes after the injection.
- Headaches.
- Fluid retention.
- Joint pain.
- Increased sensitivity to insulin.
- Reported in under 1 percent of people in studies: difficulty swallowing, dizziness, hyperactivity, drowsiness, and hives.
- Some people get small, short-lived rises in cortisol, prolactin, FSH and LH.
- Some users report increased hunger, and a few stop because of it.
- Less common but more serious: dizziness, flushing, lowered blood pressure.
- Side effects are usually mild and temporary and normally settle within the first few weeks.
- What you should not see: because the body's own brake (somatostatin) limits the response, the enlarged hands, feet and jaw, organ growth and severe insulin resistance seen with synthetic HGH are not expected at standard doses.
- Injection site reactions — pain, swelling, redness or itching — in approximately 1 in 6 patients; the most frequent adverse event.
- Facial flushing, typically brief.
- Headache.
- Fluid retention.
- Arthralgia.
- Increased insulin sensitivity.
- Treatment-related events below 1 percent: dysphagia, dizziness, hyperactivity, somnolence, urticaria.
- Small acute rises in cortisol, prolactin, FSH and LH in some individuals — generally transient and mild, but a broader hormonal footprint than newer analogues such as CJC-1295, which is part of why those were developed.
- Users report increased hunger in a minority of cases, occasionally prompting discontinuation.
- Less common but more serious: dizziness, flushing, reduced blood pressure.
- Effects are typically mild and transient, resolving within the first few weeks of therapy.
- Somatostatin feedback makes serious overdose events very rare and makes supraphysiological GH levels difficult to reach; acromegalic features, organomegaly and severe insulin resistance are not expected at standard doses.
What the evidence shows
Sermorelin was approved by the FDA in 1997 for children with growth hormone deficiency, under the brand name Geref. The maker stopped producing it in 2008 for business reasons, not safety reasons.
Walker (2006) was an editorial in Clinical Interventions in Aging. It argued that Sermorelin is a better option than synthetic HGH for ageing adults because the body's own brake hormone controls the response, the natural pulse pattern is kept, tolerance is avoided, and the pituitary gland is supported rather than suppressed. It was an opinion piece, not a trial, so the reasoning is sound but it is not proof.
Prakash and Goa (1999) reviewed Sermorelin in children. A daily injection of 30 mcg per kilogram of body weight at bedtime helped growth in children before puberty. Growth speed rose over 12 months and the effect held for 36 months. Shorter children with delayed bone age did best. The catch: growth was less than with synthetic growth hormone at similar doses, and final adult height was not known.
Merriam et al. (2003), in Endocrine, reviewed older adults. The ageing pituitary still responds to this signal, and repeated dosing lifted IGF-1 into the range of younger adults. Lean muscle went up and body fat went down with sustained treatment. Thinking test scores improved against placebo. Sleep quality did not improve with short-acting treatment in that review, and the authors said the findings did not yet justify routine use in normal ageing.
A 5-month randomised placebo-controlled trial of 19 people aged 55 to 71 found real rises in night-time growth hormone and blood IGF-1 in both sexes, with men gaining more, including better insulin sensitivity, libido and quality of life. Six months of treatment also improved tests of working memory, planning, attention and processing speed in healthy older adults.
The honest limit: most Sermorelin studies are in children, small, or reviews. The evidence in healthy adults is thinner than for tesamorelin.
Sermorelin gained FDA approval in 1997 for paediatric GH deficiency as Geref; production was discontinued in 2008 for commercial, not safety, reasons, and it remains available through compounding pharmacies off-label.
Walker (2006), an editorial in Clinical Interventions in Aging, set out the theoretical case for Sermorelin over synthetic HGH in ageing adults: somatostatin-regulated effects that prevent overdose, preserved pulsatility, avoidance of tachyphylaxis through physiological release, and support rather than suppression of pituitary function. The same paper frames pituitary recrudescence — Sermorelin stimulating hGH gene transcription and potentially preserving somatotroph capacity. This is a mechanistic framework, not a randomised trial.
Prakash and Goa (1999), a comprehensive review in BioDrugs, covered diagnostic and therapeutic use in idiopathic paediatric GH deficiency. Daily subcutaneous Sermorelin at 30 mcg/kg at bedtime promoted growth in prepubertal children, with height velocity rising significantly over 12 months and effects maintained across 36 months; shorter children with delayed bone age responded best. Growth-promoting effects were smaller than somatropin at comparable doses and final adult height was undetermined at publication.
Merriam et al. (2003) in Endocrine reviewed GHRH and ghrelin mimetics in normal ageing. The aged pituitary remains GHRH-responsive; repeated dosing normalised IGF-1 to young-adult ranges, sustained treatment increased lean mass and reduced fat mass, and cognitive testing improved versus placebo. Sleep quality did not improve with short-acting GHRH in that review, and the authors judged the data insufficient for routine clinical use in normal ageing.
Supporting data include a 5-month randomised placebo-controlled trial in 19 participants aged 55 to 71 testing GHRH analogues, which showed significant increases in nocturnal GH and serum IGF-1 in both sexes, with men showing greater anabolic benefit plus improvements in insulin sensitivity, libido and quality of life. Six months of sermorelin acetate improved fluid intelligence measures — working memory, planning and organisation, selective attention, processing speed — in healthy older adults.
Overall the evidence base in healthy adults is limited relative to tesamorelin in HIV-associated lipodystrophy: mostly paediatric, small-sample, or review-level work. Mechanism and safety are well established; outcome-level proof is not.
User reports
From public forums
The following comes from external platforms including Reddit, peptide forums and clinic reviews. It is anecdotal and does not carry the weight of published research.
Sleep is the headline. Better sleep quality is the most common and most consistent report, and it is usually the first thing people notice, often within the first 1 to 2 weeks. Faster recovery between training sessions is the second most common report.
Body composition changes are described as gradual, over 3 to 6 months: a leaner look, better muscle tone, less belly fat. Results vary a lot depending on age, starting hormone levels, diet and how consistently people train. Some users say Sermorelin works but feels more subtle than CJC-1295 or tesamorelin, which fits with how quickly Sermorelin is broken down.
On side effects, mild injection site reactions are the most reported. Some describe facial flushing for a few minutes after injecting. A small number report increased hunger, and some stopped because of it. A few report signs consistent with raised cortisol and prolactin, which matches the clinical literature.
Some users find it works less well after several months, with IGF-1 levels flattening or dropping. The usual suggestion in that situation is to add ipamorelin at a different time of day, or switch to CJC-1295 for a while.
Cost is a strong point in Sermorelin's favour. It is much cheaper than tesamorelin for what is essentially the same pathway, so most users treat it as an entry point into growth hormone peptides or a budget long-term option.
Aggregated from external platforms including Reddit, peptide forums and clinic reviews. Anecdotal, and weighted accordingly.
Improved sleep quality is the most consistently reported benefit, typically noticed within the first 1 to 2 weeks and plausibly linked to superimposing the GHRH signal on the slow-wave-sleep pulse. Accelerated inter-session recovery is the second most common report.
Body composition reports describe gradual change over 3 to 6 months — leaner appearance, improved tone, reduced abdominal adiposity — with wide inter-individual variance driven by age, baseline somatotropic status, diet and training consistency. A recurring observation is that Sermorelin feels more subtle than CJC-1295 or tesamorelin, consistent with its 10 to 20 minute half-life and rapid DPP-4 degradation.
Reported adverse effects are led by mild injection site reactions, followed by transient facial flushing post-injection. A minority report increased appetite sufficient to prompt discontinuation. Cortisol and prolactin elevations are reported in some individuals, matching literature noting small acute rises that newer analogues tend to avoid.
Tolerance reports are notable: some users describe declining efficacy over extended use with IGF-1 plateauing or falling after several months, possibly reflecting GHRH receptor downregulation. The common practical responses are adding ipamorelin at a separate time of day to recruit the ghrelin pathway, or rotating to CJC-1295 for a period.
Cost is the dominant practical argument in Sermorelin's favour — substantially below tesamorelin for the same receptor pathway — positioning it as an entry compound or a long-run budget option.
User reports are individual experiences submitted by site visitors. They are not medical advice, are not verified for accuracy, and do not reflect Amino Reference's views. Read the evidence section above and talk to a clinician. Full disclaimer.
Stacking
The most common and most logical pairing, and one of the most clinically supported combinations for long-term growth hormone support. Sermorelin works on one signal, ipamorelin on another, and together they release far more growth hormone than either alone — research shows 77 to 225 percent more than either compound used on its own. Ipamorelin is preferred because it does not spike cortisol, prolactin or ACTH the way older peptides like GHRP-6 do. Pin them together, fasted, before bed. Typical pairing: Sermorelin 200 to 300 mcg with ipamorelin 100 to 200 mcg, daily, for 8 to 12 weeks.
The reference GHRH-analogue plus GHRP pairing. Sermorelin acts at the GHRH receptor and increases the number of somatotrophs secreting; ghrelin agonists increase output per cell and suppress somatostatin, removing the brake. The synergy is reported at 77 to 225 percent greater GH release than either compound alone. Ipamorelin is the preferred GHRP because it spares cortisol, prolactin and ACTH unlike GHRP-6. Co-administered fasted pre-sleep: Sermorelin 200 to 300 mcg with ipamorelin 100 to 200 mcg daily, 8 to 12 week cycles. Also the standard answer to suspected GHRH receptor downregulation, dosed at a separate time of day.
The same pathway as Sermorelin but engineered to survive longer in the body, so it is usually a swap or a rotation rather than something to add on top. Users who plateau on Sermorelin often rotate to CJC-1295 for a period.
Also a GHRH analogue, with four substituted amino acids conferring DPP-4 resistance, a longer effective duration and a cleaner endocrine profile — notably less cortisol and prolactin drift than Sermorelin. Because both act at the same receptor, treat this as substitution or sequencing rather than additive stimulation; rotation is the common response to plateauing IGF-1.
No interaction concerns — completely different mechanism. It speeds soft tissue repair and recovery alongside the growth hormone effect. BPC-157 does not need to be taken fasted, so inject it at any time and keep Sermorelin on its own fasting schedule.
Angiogenesis- and cytoprotection-driven healing with no interaction with the somatotropic axis; can run concurrently. It also upregulates GH receptor expression in tendon fibroblasts, putting more receptor in front of the raised GH. No fasting requirement, so timing is independent of Sermorelin's fasted pre-sleep window.
No interaction concerns. It works through a different repair pathway and speeds recovery and soft tissue healing alongside Sermorelin.
Actin-sequestration-driven cell migration and systemic soft-tissue repair; no overlap with the GH axis, so it runs concurrently without timing conflict.
Promotes fat burning and body recomposition alongside Sermorelin's muscle-building effect.
GH fragment with lipolytic action and no glycaemic impact — adds fat loss without compounding GH's insulin-counter-regulatory burden.
No interaction concerns. Different mechanisms, so they can be run at the same time without timing conflicts.
Incretin-receptor agonism is mechanistically separate from the GHRH–somatotroph axis; concurrent use carries no timing conflict. Worth noting that improving glycaemia and reducing adiposity removes two of the factors that blunt GHRH-stimulated GH release.
Supports the health of mitochondria — the parts of the cell that make energy — during long-term hormone work.
Mitochondrial and anti-ageing support during extended hormone optimisation; no axis overlap.
Grouped with NAD+ as cell-health support during long-term hormone use.
Antioxidant and mitochondrial support alongside NAD+ during extended hormone optimisation.
- Testosterone replacement therapy
No interaction concerns. Sermorelin can be run alongside TRT without issues.
No pharmacological conflict with the somatotropic axis; concurrent use with testosterone replacement is unproblematic.
- L-Arginine or GABA
These may further encourage the body's own growth hormone production when taken with Sermorelin before sleep.
Non-peptide adjuncts that may further enhance endogenous GH output when co-administered pre-sleep.
Common questions
Is Sermorelin as effective as CJC-1295?
They use the same pathway and the same receptor. The difference is how long they survive in the body. CJC-1295 has four changed amino acids that resist breakdown, so it lasts longer and has a cleaner side effect profile. Sermorelin can cause small cortisol and prolactin spikes that CJC-1295 tends to avoid. For most people CJC-1295 is the preferred choice in this category, unless cost or personal response favours Sermorelin.
Both bind the same GHRH receptor and trigger the same downstream cascade; the difference is engineering. CJC-1295 without DAC substitutes four amino acids for DPP-4 resistance, giving longer effective duration and a cleaner endocrine profile. Sermorelin can produce small acute cortisol and prolactin rises that CJC-1295 tends to avoid. CJC-1295 is generally preferred unless cost or individual response favours Sermorelin.
Why would anyone choose Sermorelin over CJC-1295?
Cost, availability and individual response. Sermorelin is widely available through compounding pharmacies and some people simply respond better to it. If you tried CJC-1295 and got side effects like a head rush or a faster heart rate, Sermorelin may be worth trying. The only way to know is to run one, check your IGF-1 over 6 to 8 weeks, and judge from there.
Cost, availability and individual response. Sermorelin is widely available through compounding pharmacies, and some responders do better on it. Those who experience head rush or tachycardia on CJC-1295 may tolerate Sermorelin better. Resolution is empirical: run one, track IGF-1 over 6 to 8 weeks, evaluate.
Does Sermorelin spike cortisol and prolactin?
Clinical data shows it can cause small short-lived rises in prolactin, FSH and LH. One study, though, found that Sermorelin given into a vein or under the skin stimulated growth hormone without meaningful changes in prolactin, cortisol, glucose, glucagon or thyroid hormones. The difference may come down to dose and how it is given. In practice, some users do report symptoms that fit with raised cortisol or prolactin, and this is one reason newer versions like CJC-1295 were developed.
Clinical data shows small acute rises in prolactin, FSH and LH are possible. One study noted that intravenous or subcutaneous Sermorelin stimulates GH secretion without significant changes in prolactin, cortisol, glucose, glucagon or thyroid hormones. The discrepancy likely depends on dose and route. In practice some users report symptoms consistent with elevated cortisol or prolactin, and this broader hormonal footprint is part of the rationale for newer analogues.
Does it have to be taken on an empty stomach?
Yes. Food, especially carbohydrate, raises insulin, and raised insulin blunts the growth hormone response. Leave at least 2 hours of fasting before the injection. Bedtime dosing handles this automatically for most people if they stop eating 2 or more hours before bed.
Yes. Postprandial insulin, and elevated free fatty acids, blunt the somatotroph response to GHRH stimulation. A minimum 2-hour fast before injection is required; bedtime dosing satisfies this for most people who stop eating 2 or more hours before sleep.
Can it be taken in the morning instead of at night?
Yes. Some people prefer morning dosing for convenience, or because dosing at bedtime affects their sleep. If you dose in the morning, inject fasted and wait at least 30 minutes — ideally 2 hours — before eating. Bedtime is still generally preferred because it lines up with your body's largest natural growth hormone pulse during deep sleep.
Yes. Morning dosing is viable for convenience or where pre-sleep dosing disturbs sleep. Inject fasted and delay food by at least 30 minutes, ideally 2 hours. Bedtime remains preferred because it superimposes the exogenous GHRH signal on the dominant slow-wave-sleep GH pulse.
How long before results appear?
Sleep improvements often show up within 1 to 2 weeks. Better recovery tends to appear around weeks 3 to 6. Visible body composition change usually takes 3 to 6 months of consistent daily use. This is a slow-building tool, not a quick fix.
Sleep quality typically improves within 1 to 2 weeks. Recovery gains appear around weeks 3 to 6 as IGF-1 stabilises. Body composition change becomes visible from weeks 6 to 12 and is most pronounced across months 3 to 6. The compound shifts the GH/IGF-1 axis gradually rather than producing acute effects.
Why was Geref discontinued?
The manufacturer, EMD Serono, stopped production in 2008 for commercial reasons. The market for treating growth hormone deficiency in children was dominated by synthetic growth hormone products. The decision had nothing to do with safety.
EMD Serono discontinued production in 2008 for commercial reasons; the paediatric GH deficiency market was dominated by somatropin products. The withdrawal was not safety-driven, and Sermorelin remains available through compounding pharmacies for off-label use.
What can blunt the response to Sermorelin?
Untreated underactive thyroid can significantly reduce how well it works, so fix that first. Obesity, high blood sugar and raised free fatty acids also blunt the pituitary's response. Get diet, training and metabolic health in order before adding peptides.
Untreated hypothyroidism markedly reduces efficacy and should be corrected before starting. Obesity, hyperglycaemia and elevated free fatty acids all blunt the somatotroph response to GHRH stimulation. Exogenous GH suppresses the pituitary's response entirely through negative feedback and should not be co-administered.
References
- Walker RF. Sermorelin: A better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308.
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157.
- Merriam GR, Schwartz RS, Vitiello MV. Growth hormone-releasing hormone and growth hormone secretagogues in normal aging. Endocrine. 2003;22(1):41-48.
- Ishida J, Saitoh M, Doehner W, et al. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Commun. 2020;3(1):25-37.
- Veldhuis JD, Iranmanesh A, Ho KK, et al. Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man. J Clin Endocrinol Metab. 1991;72(1):51-59.
- Teichman SL, Neale A, Lawrence B, et al. Prolonged Stimulation of Growth Hormone and Insulin-Like Growth Factor I Secretion by CJC-1295. J Clin Endocrinol Metab. 2006;91(3):799-805.
This entry has been reviewed and expanded with additional reference material. Units are recomputed from the stated protocol.